「国际肝病」一线NA降低HCC无差异，再添新证据 —ETV优于二线药物，ETV vs TDF无差异( 二 )

参考文献：（可上下滑动查看）
1.Choi J, Kim HJ, Lee J, et al. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.JAMA Oncol. 2019;5(1):30-36.
2.Kong Y, Jia J, Yang HI.Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. JAMA Oncol. 2019;5(6):915-916.
3.Wang X, Liu X, Dang Z, et al. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver. 2019 Oct 18. [Epub ahead of print]
4.Kim SU, Seo YS, Lee HA, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-na?ve chronic hepatitis B in South Korea. J Hepatol. 2019;71(3):456-464.
5.Lee SW, Kwon JH, Lee HL, et al.Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na?ve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.Gut. 2019 Oct 31. [Epub ahead of print]
6.Hsu YC, Wong GL, Chen CH, et al. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. Am J Gastroenterol. 2020;115(2):271-280.
7.European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol. 2017;67(2):370-398.
8.中华医学会感染病学分会中华医学会肝病学分会. 慢性乙型肝炎防治指南（2019年版）. 中华肝脏病杂志. 2019; 27(12):938-961.
在看点这里